Cabozantinib with nivolumab for untreated advanced renal cell carcinoma [ID6184]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 April 2024
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Renal cell carcinoma Pathways Pilot [ID6186]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma TS ID 11882Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC